# Biodesix (BDSX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BDSX
## Company Profile
- Ticker: BDSX
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics
## Stock Data
- Close: 22.78 USD
- Market cap: 159893690.96 USD
- Last updated: 2026-08-05
## Business Overview
### Lung-Disease Diagnostics
Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology. Its tests combine multiple analytical technologies with clinical evidence and laboratory operations.
### Diagnostic Testing
The company provides blood-based and other diagnostic tests that help physicians characterize disease, guide treatment and monitor patients. Its commercial laboratory infrastructure supports ordering, sample processing and reporting for routine clinical use.
### Development Services
Biodesix also works with biopharmaceutical, life-sciences and research organizations to develop diagnostics, tools and therapeutics. These services combine scientific, technological and operational capabilities and can support biomarker strategy from research through clinical development.
## Why The Stock Is Moving

The latest monitored company update is “Biodesix Announces Second Quarter 2026 Results and Highlights.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Biodesix’s catalysts are diagnostic-test adoption, oncology workflow growth, and whether the platform can keep building recurring testing revenue. The market will care about utilization and reimbursement more than a single event.

## Recent News
- 2026-08-05 20:01 EST — [Biodesix Announces Second Quarter 2026 Results and Highlights](https://biopharmsignal.com/news/BDSX/biodesix-announces-second-quarter-2026-results-and-highlights-45941193) — Source: Biodesix
- 2026-08-04 10:00 EST — [Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference](https://biopharmsignal.com/news/BDSX/biodesix-to-participate-in-canaccord-genuity-s-46th-annual-growth-conference-9a24f4ae) — Source: Biodesix
- 2026-07-22 10:00 EST — [Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/BDSX/biodesix-to-report-second-quarter-2026-financial-results-on-august-5-2026-cf36c056) — Source: Biodesix
- 2026-05-21 10:00 EST — [Biodesix to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/BDSX/biodesix-to-participate-in-upcoming-investor-conferences-ab591711) — Source: Biodesix
- 2026-05-11 13:17 EST — [Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy](https://biopharmsignal.com/news/BDSX/biodesix-announces-ats-2026-presentations-providing-real-world-clinical-evidence-45441597) — Source: Biodesix